[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100369031":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":18,"responsibleParty":76,"collaborators":7,"id":78,"slug":7,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":7,"eligibilityCriteria":82,"healthyVolunteers":79,"sex":83,"minAge":84,"maxAge":7,"enrollmentInfo":85,"targetDuration":88,"studyType":89,"phases":7,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Duke University","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Joseph Salama, MD","PRINCIPAL_INVESTIGATOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Clinical Trials Office","CONTACT","(919) 668 3726","RadOnc-Clinical_Trials@dm.duke.edu",[19,35,49,57,68],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Duke Cancer Institute Cary","RECRUITING","Cary","North Carolina","27518","United States",{"type":27,"coordinates":28},"Point",[29,30],-78.78112,35.79154,{"lat":30,"lon":29},[33],{"name":14,"role":15,"phone":34,"phoneExt":7,"email":17},"919-668-3726",{"facility":36,"status":21,"city":37,"state":23,"zip":38,"country":25,"cosmosGeoPoint":39,"geoPoint":43,"contacts":44},"Durham Veterans Administration Health Care System (DVAHCS)","Durham","27705",{"type":27,"coordinates":40},[41,42],-78.89862,35.99403,{"lat":42,"lon":41},[45,48],{"name":46,"role":15,"phone":7,"phoneExt":7,"email":47},"Josephine Gaston, RN","josephine.gaston@va.gov",{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"facility":50,"status":21,"city":37,"state":23,"zip":51,"country":25,"cosmosGeoPoint":52,"geoPoint":54,"contacts":55},"Duke University Medical Center","27710",{"type":27,"coordinates":53},[41,42],{"lat":42,"lon":41},[56],{"name":14,"role":15,"phone":34,"phoneExt":7,"email":17},{"facility":58,"status":21,"city":59,"state":23,"zip":60,"country":25,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Duke Women's Cancer Care Raleigh","Raleigh","27607",{"type":27,"coordinates":62},[63,64],-78.63861,35.7721,{"lat":64,"lon":63},[67],{"name":14,"role":15,"phone":34,"phoneExt":7,"email":17},{"facility":69,"status":21,"city":59,"state":23,"zip":70,"country":25,"cosmosGeoPoint":71,"geoPoint":73,"contacts":74},"Duke Raleigh Hospital","27609",{"type":27,"coordinates":72},[63,64],{"lat":64,"lon":63},[75],{"name":14,"role":15,"phone":34,"phoneExt":7,"email":17},{"type":77,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100369031",false,"NCT04085029","Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment\n* Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)\n* Patient must sign study-specific informed consent\n\nExclusion Criteria:\n\n• None","ALL","18 Years",{"count":86,"type":87},300,"ESTIMATED","10 Years","OBSERVATIONAL","The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.",[92,93],"Oligometastasis","Metastatic Cancer",[95],"Ablative radiotherapy","2026-02-03",{"date":98,"type":99},"2026-02-05","ACTUAL",{"date":101,"type":99},"2019-09-26",{"date":103,"type":87},"2029-09",{"name":5,"class":6},5]